公开(公告)号：EP4406599A2

公开(公告)日：2024-07-31

申请号：EP24162497.2

申请日：2016-08-01

申请人： BioMarin Pharmaceutical Inc.

发明人： BULLENS, Sherry ,  BUNTING, Stuart ,  CHOU, Tianwei ,  OKHAMAFE, Augustus O ,  PRICE, Christopher P. ,  WENDT, Daniel J. ,  YAP, Clarence

IPC分类号： A61P19/08

CPC分类号： A61K38/1709 ,  A61K38/2242 ,  A61K9/19 ,  A61K9/0019 ,  A61K47/12 ,  A61K47/26 ,  A61K47/20 ,  A61P19/08

摘要： The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.

公开(公告)号：EP3328416A1

公开(公告)日：2018-06-06

申请号：EP16750584.1

申请日：2016-08-01

申请人： BioMarin Pharmaceutical Inc.

发明人： BULLENS, Sherry ,  BUNTING, Stuart ,  CHOU, Tianwei ,  OKHAMAFE, Augustus, O. ,  PRICE, Christopher, P. ,  WENDT, Daniel, J. ,  YAP, Clarence

IPC分类号： A61K38/22 ,  A61K38/17 ,  A61P19/08

CPC分类号： A61K38/2242 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/1709 ,  A61K47/10 ,  A61K47/12 ,  A61K47/183 ,  A61K47/26

摘要： The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.

公开(公告)号：EP4406599A3

公开(公告)日：2024-11-06

申请号：EP24162497.2

申请日：2016-08-01

申请人： BioMarin Pharmaceutical Inc.

发明人： BULLENS, Sherry ,  BUNTING, Stuart ,  CHOU, Tianwei ,  OKHAMAFE, Augustus O ,  PRICE, Christopher P. ,  WENDT, Daniel J. ,  YAP, Clarence

IPC分类号： A61K9/00 ,  A61K9/19 ,  A61K38/17 ,  A61K38/22 ,  A61K47/12 ,  A61K47/20 ,  A61K47/26 ,  A61P19/08

摘要： The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.